Getting latest data loading
Home / Special reports pages / GlaxoSmithKline Page 4

This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.

GlaxoSmithKline Page 4

GlaxoSmithKline (GSK)

Will shares return to 2017 highs above 1700p (+14%) or fall to 2-year lows of 1230p (-17%)?
  • Having failed to overcome 4-year resistance in June, shares have fallen to key support at 1475p?
  • Stochastics have recovered from oversold; while RSI continues to hover around the same level
  • Momentum remains negative; Directional Indicators are diverging bearishly
  • Most brokers suggest holding or buying GSK, with an astonishing 92% seeing upside from the current price

 

Broker Consensus: 38% Buy, 56% Hold, 6% Sell

Bullish: Oddo BHF, Buy, Target 2100p, +41% (27 July)

Average Target: 1727.62p, +16% (18 Aug)

Bearish: Societe Generale, Sell, Target 1300p, -13% (26 Jun)

 

Pricing and consensus data sourced from Bloomberg on 18 August. Please contact us for a full, up to date rundown.

« Back to Category

This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.

Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research

Comments are closed.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
.